A global pharmaceutical company was considering moving to Office 365 while renewing their Enterprise Agreement and consolidating operations. Their goal was to reduce or maintain the cost of the existing Enterprise Agreement, which was about $120M, so they needed an expert opinion to review their licensing needs regarding their ongoing mergers and acquisitions.
The company had experience with negotiating Microsoft contracts, but did not have a comprehensive understanding of the licensing and software assurance rules, particularly around divesting and acquiring separate business units.
The company was in the process of divesting an organization (a clinical diagnostic company) as well as bringing on another (a bio-pharma) during the term of the new Enterprise Agreement.
Miro was brought in to conduct a Microsoft license review of all three entities. With Miro’s assistance, the company was able to determine its current compliance status as a baseline. The team then determined what new licenses would be gained from the acquisition, lost in the divestiture, and what licenses they’d need to buy to “true-up” for the shortfall.
Additionally, the three entities each had their own EA agreements which would need to be merged. Miro’s expert analysis resulted in a singular Enterprise Agreement for the company with the appropriate licensing at a greatly discounted price.
The company secured discounting well beyond Level “D”, extending even to True-Up licenses, as well as incentives including Office 365 professional services, and Business Incentive Funding (“BIF”). The company was able to save over $18M in costs in the final contract price.